<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394771</url>
  </required_header>
  <id_info>
    <org_study_id>DR-ASC-201</org_study_id>
    <nct_id>NCT00394771</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale</brief_title>
  <official_title>A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women Using One of Three Different Doses of DR-1031 Oral Contraceptive Compared to Seasonale Oral Contraceptive Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duramed Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 4-arm study to evaluate and compare bleeding patterns between three different doses
      of DR-1031 oral contraceptive with Seasonale oral contraceptive. Study participants will
      receive physical and gynecological exams, including Pap smear. During the study, all
      participants will be required to complete a diary
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2, prospective, multicenter, double-blinded, randomized study is designed to
      evaluate and compare bleeding patterns in women using one of three different doses of DR-1031
      oral contraceptive with Seasonale oral contraceptive.

      Patients who meet all study entrance criteria will be randomly assigned to one of four
      treatment groups,

      The overall study duration will be approximately 9 months; this will include a screening
      period of approximately 4 weeks, a run-in period of 4 weeks, a treatment period of
      approximately 6 months (two,91-day cycles) and a final study visit occurring 14-21 days after
      completion of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)</measure>
    <time_frame>Day 92-176</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days With Bleeding During Active Cycle 1 (Day 1-84)</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days With Bleeding During Active Cycle 2 (Day 92-176)</measure>
    <time_frame>Day 92-176</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bleeding Day</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection.
Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Bleeding Severity During Active Cycle 1 (Day 1-84)</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity.
See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)</measure>
    <time_frame>Day 85-91</time_frame>
    <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)</measure>
    <time_frame>Day 177-183</time_frame>
    <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)</measure>
    <time_frame>Day 92-176</time_frame>
    <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)</measure>
    <time_frame>Day 85-91</time_frame>
    <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)</measure>
    <time_frame>Day 177-183</time_frame>
    <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)</measure>
    <time_frame>Day 1-84</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)</measure>
    <time_frame>Day 92-176</time_frame>
    <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">567</enrollment>
  <condition>Breakthrough Bleeding</condition>
  <arm_group>
    <arm_group_label>Low Dose DR-1031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midrange Dose DR-1031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose DR-1031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seasonale</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DR-1031</intervention_name>
    <description>Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.</description>
    <arm_group_label>Low Dose DR-1031</arm_group_label>
    <arm_group_label>Midrange Dose DR-1031</arm_group_label>
    <arm_group_label>High Dose DR-1031</arm_group_label>
    <other_name>levonorgestrel/ethinyl estradiol</other_name>
    <other_name>Quartette速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seasonale速</intervention_name>
    <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.</description>
    <arm_group_label>Seasonale</arm_group_label>
    <other_name>levonorgestrel/ethinyl estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Portia速</intervention_name>
    <description>Portia速 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.</description>
    <arm_group_label>Low Dose DR-1031</arm_group_label>
    <arm_group_label>Midrange Dose DR-1031</arm_group_label>
    <arm_group_label>High Dose DR-1031</arm_group_label>
    <arm_group_label>Seasonale</arm_group_label>
    <other_name>levonorgestrel/ethinyl estradiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal

          -  Not pregnant or breastfeeding

          -  Agree to use back-up non-hormonal contraception for study period

        Exclusion Criteria:

          -  Any contraindication to the use of oral contraceptives

          -  Pregnancy within the last 3 months

          -  Smoking &gt;10 cigarettes per day
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duramed Medical Monitor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duramed Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Stratford</city>
        <state>Connecticut</state>
        <zip>06615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Riverdale</city>
        <state>Maryland</state>
        <zip>20737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>N. Las Vegas</city>
        <state>Nevada</state>
        <zip>89030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duramed Investigational Site</name>
      <address>
        <city>Williston</city>
        <state>Vermont</state>
        <zip>05495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2006</study_first_submitted>
  <study_first_submitted_qc>October 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2006</study_first_posted>
  <results_first_submitted>April 25, 2013</results_first_submitted>
  <results_first_submitted_qc>April 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2013</results_first_posted>
  <disposition_first_submitted>June 8, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2011</disposition_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral contraceptives</keyword>
  <keyword>breakthrough bleeding</keyword>
  <keyword>spotting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 988 subjects were screened for participation in this study, and 567 took at least one dose of investigational product (Safety population).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose DR-1031</title>
          <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="P2">
          <title>Midrange Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="P3">
          <title>High Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="P4">
          <title>Seasonale</title>
          <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140">Safety population of treated participants</participants>
                <participants group_id="P2" count="136">Safety population of treated participants</participants>
                <participants group_id="P3" count="143">Safety population of treated participants</participants>
                <participants group_id="P4" count="148">Safety population of treated participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="110">At least one completed 91 day cycle of treatment</participants>
                <participants group_id="P2" count="110">At least one completed 91 day cycle of treatment</participants>
                <participants group_id="P3" count="108">At least one completed 91 day cycle of treatment</participants>
                <participants group_id="P4" count="120">At least one completed 91 day cycle of treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet protocol requirements</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose DR-1031</title>
          <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="B2">
          <title>Midrange Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="B3">
          <title>High Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="B4">
          <title>Seasonale</title>
          <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="120"/>
            <count group_id="B5" value="448"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="6.88"/>
                    <measurement group_id="B2" value="30.5" spread="7.02"/>
                    <measurement group_id="B3" value="30.7" spread="7.61"/>
                    <measurement group_id="B4" value="30.6" spread="6.90"/>
                    <measurement group_id="B5" value="30.5" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.6" spread="28.84"/>
                    <measurement group_id="B2" value="153.6" spread="27.18"/>
                    <measurement group_id="B3" value="156.0" spread="30.79"/>
                    <measurement group_id="B4" value="151.9" spread="30.03"/>
                    <measurement group_id="B5" value="154.4" spread="29.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="4.13"/>
                    <measurement group_id="B2" value="25.7" spread="4.24"/>
                    <measurement group_id="B3" value="26.0" spread="4.59"/>
                    <measurement group_id="B4" value="25.5" spread="4.41"/>
                    <measurement group_id="B5" value="25.9" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.2" spread="10.74"/>
                    <measurement group_id="B2" value="114.4" spread="10.34"/>
                    <measurement group_id="B3" value="115.6" spread="9.31"/>
                    <measurement group_id="B4" value="112.8" spread="10.23"/>
                    <measurement group_id="B5" value="114.2" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="8.85"/>
                    <measurement group_id="B2" value="72.9" spread="7.46"/>
                    <measurement group_id="B3" value="71.8" spread="7.72"/>
                    <measurement group_id="B4" value="71.4" spread="8.44"/>
                    <measurement group_id="B5" value="72.1" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="9.85"/>
                    <measurement group_id="B2" value="73.7" spread="8.90"/>
                    <measurement group_id="B3" value="73.7" spread="9.17"/>
                    <measurement group_id="B4" value="71.9" spread="9.07"/>
                    <measurement group_id="B5" value="73.3" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Contraceptive Use History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Continuous User</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior User</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fresh-Start</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
        <time_frame>Day 1-84</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="0" upper_limit="67"/>
                    <measurement group_id="O2" value="13.5" lower_limit="0" upper_limit="65"/>
                    <measurement group_id="O3" value="15" lower_limit="0" upper_limit="69"/>
                    <measurement group_id="O4" value="15" lower_limit="0" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days With Bleeding During Active Cycle 1 (Day 1-84)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
        <time_frame>Day 1-84</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Days With Bleeding During Active Cycle 1 (Day 1-84)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="49"/>
                    <measurement group_id="O3" value="4" lower_limit="0" upper_limit="47"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days With Bleeding During Active Cycle 2 (Day 92-176)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
        <time_frame>Day 92-176</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Days With Bleeding During Active Cycle 2 (Day 92-176)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="49"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Bleeding Day</title>
        <description>Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection.
Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.</description>
        <time_frame>Day 1-84</time_frame>
        <population>ITT population. However this data was not summarized due to limitations in the diary data.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Bleeding Day</title>
          <description>Time to first bleeding day was defined as the time between the start of intervention until the first day when bleeding was heavy enough to require the use of sanitary protection.
Data are not summarized due to limitations in the diary data and an inability to accurately determine a participant's first day of bleeding.</description>
          <population>ITT population. However this data was not summarized due to limitations in the diary data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Bleeding Severity During Active Cycle 1 (Day 1-84)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity.
See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.</description>
        <time_frame>Day 1-84</time_frame>
        <population>ITT population. However data was not summarized due to limitations in the diary data.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Bleeding Severity During Active Cycle 1 (Day 1-84)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.
Data was not summarized due to limitations in the diary data, and an inability to accurately determine the maximum bleeding severity.
See pre-specified analyses for Number of Moderate to Heavy Bleeding Days.</description>
          <population>ITT population. However data was not summarized due to limitations in the diary data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
        <time_frame>Day 92-176</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Days With Bleeding and/or Spotting During Active Cycle 2 (Day 92-176)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Spotting does not require sanitary protection.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="0" upper_limit="74"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="70"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="74"/>
                    <measurement group_id="O4" value="6" lower_limit="0" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)</title>
        <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.</description>
        <time_frame>Day 85-91</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 1 (Day 85-91)</title>
          <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 1.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)</title>
        <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.</description>
        <time_frame>Day 177-183</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Bleeding and/or Spotting Days During the 7-day Withdrawal During Cycle 2 (Day 177-183)</title>
          <description>Participants are categorized by the duration of bleeding that occurred during the scheduled 7-day withdrawal period for Cycle 2.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)</title>
        <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
        <time_frame>Day 1-84</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Reporting Hormone-Related Symptoms During Active Cycle 1 (Day 1-84)</title>
          <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)</title>
        <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
        <time_frame>Day 92-176</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Reporting Hormone-Related Symptoms During Active Cycle 2 (Day 92-176)</title>
          <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)</title>
        <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
        <time_frame>Day 85-91</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 1 (Day 85-91)</title>
          <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)</title>
        <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
        <time_frame>Day 177-183</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Reporting Hormone-Related Symptoms During the 7-day Withdrawal Cycle 2 (Day 177-183)</title>
          <description>Hormone-related symptoms include breast tenderness/pain, headache, bloating, pelvic pain, anxiety, depression, and irritability.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
        <time_frame>Day 1-84</time_frame>
        <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate to Heavy Bleeding Days During Active Cycle 1 (Day 1-84)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
          <population>Intent to treat (ITT) population of participants who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="19"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)</title>
        <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
        <time_frame>Day 92-176</time_frame>
        <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose DR-1031</title>
            <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O2">
            <title>Midrange Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O3">
            <title>High Dose DR-1031</title>
            <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
          </group>
          <group group_id="O4">
            <title>Seasonale</title>
            <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate to Heavy Bleeding Days During Active Cycle 2 (Day 92-176)</title>
          <description>Bleeding is defined as a flow heavy enough to require sanitary protection. Participants recorded in the diary days when they had bleeding, and whether they considered the bleeding to be light, moderate or heavy.</description>
          <population>Intent to treat (ITT) population of participants who were still active in the study and who completed the relevant pages in the patient diary.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to Day 256 (longest treatment plus 14 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose DR-1031</title>
          <description>42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="E2">
          <title>Midrange Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="E3">
          <title>High Dose DR-1031</title>
          <description>21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.</description>
        </group>
        <group group_id="E4">
          <title>Seasonale</title>
          <description>84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Polytraumatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Details of the study and its results shall not be publicized or published in any form to cooperative publication without prior, written consent of sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products, R&amp;D Inc.</organization>
      <phone>215-591-3000</phone>
      <email>ustevatrials@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

